Wind Stocks Alert: A-Power Energy (Nasdaq: APWR), Clean Wind Energy Tower (OTCBB: CWET), Gamesa (GAM.MC) and Vestas Wind (Copenhagen: VWS.CO)
, Inc. (OTCBB: CWET), Gamesa Corporacion Tecnologica, S.A. (GAM.MC) and Vestas Wind Systems (Copenhagen: VWS.CO ). Big deals are in the wind for the sector with news that Huaneng Renewables Corp, the wind power division of China Huaneng Group, is now moving forward with its estimated $1 Billion IPO and Gamesa made headlines with news that Caparo Energy placed a $2-Billion order for wind turbines.
Gamesa recently announced that it has signed a framework agreement with power company Caparo Energy India Limited (CEIL) to deliver turbines with combined capacity of 2,000 MW over the next five years.
The deal, the largest one of its kind ever signed in India and one of the biggest in the wind energy market anywhere in the world, encompasses the delivery, installation and start-up of Gamesa's G58-850 kW and G97-2.0 MW turbines between 2012 and 2016. The contract calls for Gamesa to supply Caparo Energy with about 150 MW of turbine capacity in 2012.
Wind Stocks
A-Power Energy Generation Systems, Ltd. (Nasdaq: APWR) trading at $3.44, up 0.02 (0.58%)
Broadwind Energy, Inc. (NasdaqGS: BWEN ) trading at $1.78
China Ming Yang Wind Power Group (NYSE: MY ) trading at $7.79
China Longyuan Power Group Corp Ltd (HKG: 0916) trading $8.26
Clean Wind Energy Tower, Inc. (OTCBB: CWET) trading at $0.28
Gamesa Corporacion Tecnologica, S.A. (GAM.MC) trading at $ 6.6450, up 0.1420 (2.18%)
Vestas Wind Systems (Copenhagen: VWS.CO ) trading at $ 165.70. up 5.40 (3.37%)
Market Snapshot
Dow 12,518.06 -87.26 -0.69%
Nasdaq 2,805.32 -17.99 -0.64%
S&P 500 1,333.77 -9.83 -0.73%
10 Yr Bond (%) 3.1600% -0.0110
Oil 96.80 -1.64 -1.67%
Recent Wind News:
Gamesa and Caparo announce strategic agreement for 2,000 MW supply
17 May 2011
2,000 MW to be commissioned progressively by 2016
The turbines will be manufactured at Gamesa factories in India. The deal enables Gamesa to sell its first G97-2.0 MW turbines in India
Gamesa previously announced that it will invest more than 60 million euros through 2012 to build three plants to meet booming demand in the Indian market. After only 18 months in India, Gamesa has become the country’s No. 3 wind energy manufacturing group
Full news: http://www.gamesa.es/en/communication/news/gamesa-and-caparo-announce-strategic-agreement-for-2000-mw-supply.html?idCategoria=0&fechaDesde=&especifica=0&texto=&fechaHasta=
Vestas receives 200 MW order in Kansas, USA
18 May. 2011- Vestas has received a 200 MW order for 111 V90-1.8 MW turbines from Enel
With reference to Vestas Wind Systems A/S’ company announcement No. 22/2011 of 18 May 2011, Vestas has received a 200 MW order for 111 V90-1.8 MW turbines from Enel Green Power North America, Inc., for the Caney River wind-energy project in Elk County, Kansas, USA.
The contract includes delivery and commissioning along with a five-year service and maintenance agreement. Delivery is scheduled for the second half of 2011 and commissioning is expected in late 2011.
Clean Wind Energy Tower (OTCBB: CWET) Files "Atmospheric Energy Extraction Devices & Methods" Patent for Wind Tower
ANNAPOLIS, MD - May 5, 2011 (InvestorIdeas.com Newswire) - Clean Wind Energy Tower, Inc. (OTCBB: CWET), a clean energy company developing Downdraft Towers, reports it has filed with the United States Patent & Trademark Office "A Petition to Make Special Under the Accelerated Examination Program," a patent application titled Atmospheric Energy Extraction Devices and Methods.
The application covers the addition of specific external design components, physical structure and systems that both substantially enhances structural integrity of the tower and captures wind directly striking the external vertical surfaces of the downdraft tower from any direction, beyond those winds already induced into the internal tube of the tower, and also enhances slow moving air to create downburst winds, substantially increasing total power generation of a single tower unit.
Full news: http://www.investorideas.com/CO/CWE/news/2011/05051.asp
Research more wind stocks with the renewable energy stocks directory:
http://www.investorideas.com/Companies/RenewableEnergy/Stock_List.asp
Wind Company Snapshot
Clean Wind Energy Tower, Inc. (OTCBB: CWET) was established to commercialize a number of proven and validated technologies and construction systems into a single large downdraft tower structure that produces abundant inexpensive electricity.
www.cleanwindenergytower.com
Visit the CWET showcase page at Investorideas.com: http://www.investorideas.com/CO/CWE/
About Investorideas.com and our Green Investor content:
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Sign up at Investor Ideas for free investor alerts including news on wind stocks
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure: The following news is part of the Clean Wind Energy Tower, Inc. (OTCBB: CWET) advertising program with Investorideas.com. Clean Wind Energy, Inc. compensates investorideas.com (one thousand five hundred per month, 100,000 144 shares) to be showcased as a renewable energy stock within its hub of sites and blogs.Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and its management and is not the opinion of Investorideas.com.
Learn more: www.InvestorIdeas.com/About/Disclaimer.asp
For more information about Investorideas.com contact:
800.665.0411, Email: dvanzant@investorideas.com or cvanzant@investorideas.com
Friday, May 20, 2011
Biotech/Medical Technology Stock News; Aethlon Medical (OTCBB: AEMD) Introduces the Aethlon ADAPT System, Adaptive Dialysis-Like Affinity Platform
SAN DIEGO � May 20, 2011 (Investorideas.com newswire) Biotech/Medical Technology Stock News - Aethlon Medical, Inc. (OTCBB: AEMD), a company creates devices to address infectious disease and cancer, announces the introduction of the Aethlon ADAPT�. The ADAPT System is an adaptive dialysis-like affinity platform technology that provides a novel and potentially expedited commercialization pathway for monoclonal antibodies and other affinity drug agents. The platform technology allows for single or multiple biologic agents to be immobilized within a therapeutic filtration design that results in a significantly less burdensome medical device regulatory approval pathway compared with the pathway for drugs or biologics.
The Company will market the Aethlon ADAPT™ system to drug developers as the basis for new therapeutic devices that target high-risk disease conditions. The Aethlon ADAPT™ system allows for the selective removal of disease-related particles from the entire circulatory system without the loss of essential blood components. It eliminates the need to infuse drug agents into the body as blood filtration occurs outside of the body. As a result, new devices evolved from this platform will not add drug toxicity or drug-drug interaction risks if combined with other therapies. The Aethlon ADAPT™ system also provides the potential to immobilize greater quantities of therapeutic drug agents compared with amounts that can be safely administered systemically. The platform may also be utilized to immobilize a cocktail of drug agents within a single device to address multiple factors underlying a single disease condition.
"The Aethlon ADAPT™ system provides the drug industry a new regulatory and commercialization pathway for their monoclonal antibodies and affinity drug agents," stated Aethlon CEO Jim Joyce. "The timing for introducing our platform could not be better considering the scope of increasing and unpredictable regulatory challenges faced by therapeutic drug developers."
The genesis of the Aethlon ADAPT™ system is the Aethlon Hemopurifier�, a broad-spectrum antiviral device that immobilizes a single lectin-affinity agent to bind circulating viruses, immunosuppressive proteins and disease-enhancing exosomes associated with both infectious diseases and cancer. Human studies of the Hemopurifier� have demonstrated average viral-load reductions exceeding 50% during four-hour treatment periods in individuals infected with hepatitis C virus (HCV) and HIV, without the administration of antiviral drugs. A human study is now underway to test the ability of the Aethlon Hemopurifier� to improve clinical outcomes in patients receiving HCV drug therapy.
On April 1, 2011 the Company leveraged the principles of the Aethlon ADAPT™ system to propose a new device that would reduce the incidence of sepsis in wounded military personnel through a contract response to a dialysis-like therapeutics program offered by the Defense Advanced Research Projects Agency (DARPA). Aethlon is currently preparing a submission to another government agency that would propose the use of the Aethlon ADAPT™ system to create a third company-owned therapeutic device.
Since the beginning of 2011, Aethlon Medical has expanded its channels for early revenue generation beyond the candidate use of its Hemopurifier� in HCV care. In addition to potential development revenues from new devices created from the Aethlon ADAPT™ system, the Company has positioned itself to be a candidate recipient of contract and grant income from government agency solicitations, and is considering the launch of a research diagnostic tool line developed by its wholly owned subsidiary Exosome Sciences, Inc.
About Aethlon Medical
At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.
Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.
Human studies have documented the ability of our Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs. However, our initial clinical and commercialization focus is to establish our Hemopurifier® as an adjunct therapy to enhance the benefit of both infectious disease and cancer treatment regimens. In this regard, we plan to commercialize our Hemopurifier® in India as we advance our clinical strategies in the United States and the European Union. In vitro studies conducted by government and non-government research institutes have also verified that our Hemopurifier® has broad-spectrum capabilities against bioterror and emerging pandemic threats. These studies have confirmed the capture of Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.
As a therapeutic device, the Hemopurifier® provides us with a pipeline into four significant market opportunities:
In design, our Hemopurifier® is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system. In application, blood circulation is established into the Hemopurifier® via a catheter or other blood access device. Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier® in as little as 15 minutes.
Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) is focused on the development of exosome-targeted products and services that improve cancer diagnosis, provide post-treatment cancer surveillance, and aid in the discovery of biomarkers that allow doctors to optimize patient therapy. Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the company's ability to commercialize its Hemopurifier® in India, capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
John P. Salvador
Director, Communications & Investor Relations
858.459.7800 x307
jps@aethlonmedical.com
SAN DIEGO � May 20, 2011 (Investorideas.com newswire) Biotech/Medical Technology Stock News - Aethlon Medical, Inc. (OTCBB: AEMD), a company creates devices to address infectious disease and cancer, announces the introduction of the Aethlon ADAPT�. The ADAPT System is an adaptive dialysis-like affinity platform technology that provides a novel and potentially expedited commercialization pathway for monoclonal antibodies and other affinity drug agents. The platform technology allows for single or multiple biologic agents to be immobilized within a therapeutic filtration design that results in a significantly less burdensome medical device regulatory approval pathway compared with the pathway for drugs or biologics.
The Company will market the Aethlon ADAPT™ system to drug developers as the basis for new therapeutic devices that target high-risk disease conditions. The Aethlon ADAPT™ system allows for the selective removal of disease-related particles from the entire circulatory system without the loss of essential blood components. It eliminates the need to infuse drug agents into the body as blood filtration occurs outside of the body. As a result, new devices evolved from this platform will not add drug toxicity or drug-drug interaction risks if combined with other therapies. The Aethlon ADAPT™ system also provides the potential to immobilize greater quantities of therapeutic drug agents compared with amounts that can be safely administered systemically. The platform may also be utilized to immobilize a cocktail of drug agents within a single device to address multiple factors underlying a single disease condition.
"The Aethlon ADAPT™ system provides the drug industry a new regulatory and commercialization pathway for their monoclonal antibodies and affinity drug agents," stated Aethlon CEO Jim Joyce. "The timing for introducing our platform could not be better considering the scope of increasing and unpredictable regulatory challenges faced by therapeutic drug developers."
The genesis of the Aethlon ADAPT™ system is the Aethlon Hemopurifier�, a broad-spectrum antiviral device that immobilizes a single lectin-affinity agent to bind circulating viruses, immunosuppressive proteins and disease-enhancing exosomes associated with both infectious diseases and cancer. Human studies of the Hemopurifier� have demonstrated average viral-load reductions exceeding 50% during four-hour treatment periods in individuals infected with hepatitis C virus (HCV) and HIV, without the administration of antiviral drugs. A human study is now underway to test the ability of the Aethlon Hemopurifier� to improve clinical outcomes in patients receiving HCV drug therapy.
On April 1, 2011 the Company leveraged the principles of the Aethlon ADAPT™ system to propose a new device that would reduce the incidence of sepsis in wounded military personnel through a contract response to a dialysis-like therapeutics program offered by the Defense Advanced Research Projects Agency (DARPA). Aethlon is currently preparing a submission to another government agency that would propose the use of the Aethlon ADAPT™ system to create a third company-owned therapeutic device.
Since the beginning of 2011, Aethlon Medical has expanded its channels for early revenue generation beyond the candidate use of its Hemopurifier� in HCV care. In addition to potential development revenues from new devices created from the Aethlon ADAPT™ system, the Company has positioned itself to be a candidate recipient of contract and grant income from government agency solicitations, and is considering the launch of a research diagnostic tool line developed by its wholly owned subsidiary Exosome Sciences, Inc.
About Aethlon Medical
At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.
Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.
Human studies have documented the ability of our Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs. However, our initial clinical and commercialization focus is to establish our Hemopurifier® as an adjunct therapy to enhance the benefit of both infectious disease and cancer treatment regimens. In this regard, we plan to commercialize our Hemopurifier® in India as we advance our clinical strategies in the United States and the European Union. In vitro studies conducted by government and non-government research institutes have also verified that our Hemopurifier® has broad-spectrum capabilities against bioterror and emerging pandemic threats. These studies have confirmed the capture of Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.
As a therapeutic device, the Hemopurifier® provides us with a pipeline into four significant market opportunities:
- Cancer: A treatment candidate to improve patient responsiveness to established cancer therapies by removing immunosuppressive exosomes from circulation.
- Hepatitis-C Virus (HCV): As an adjunct therapy to accelerate viral load reduction at the outset of standard of care drug regimens.
- Human Immunodeficiency Virus (HIV): Provides a potential therapeutic option for HIV-infected individuals to manage disease progression once they become resistant to antiviral drug regimens.
- Bioterror and Pandemic Threats: Represents the most advanced broad-spectrum strategy to address untreatable bioterror and emerging pandemic threats.
In design, our Hemopurifier® is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system. In application, blood circulation is established into the Hemopurifier® via a catheter or other blood access device. Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier® in as little as 15 minutes.
Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) is focused on the development of exosome-targeted products and services that improve cancer diagnosis, provide post-treatment cancer surveillance, and aid in the discovery of biomarkers that allow doctors to optimize patient therapy. Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the company's ability to commercialize its Hemopurifier® in India, capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
John P. Salvador
Director, Communications & Investor Relations
858.459.7800 x307
jps@aethlonmedical.com
AETHLON MEDICAL INC (OTC BB: AEMD) is a Showcase biotech, biodefense and defense stock on Investorideas.com ($one thousand five hundred per month, $five thousand per month in 144 stock)
Effective March 15, 2011
Effective March 15, 2011
Stem Cell Stock News; Q&A with Stem Cell Company, Vitro Diagnostics, Inc. dba Vitro Biopharma (OTCQB: VODG)
POINT ROBERTS, Wash., May 20,2011 - www.InvestorIdeas.com, a leader in investor research including biotech and stem cell stocks, issues a Q&A with Dr. James Musick, Chief Executive Officer of stem cell company, Vitro Diagnostics, Inc. dba Vitro Biopharma (OTCQB: VODG).
Q Investorideas.com
Your company's stem cell technology focuses on adult stem cells that are derived from human tissues without sacrifice of embryos. Can you give us more detail and explain how; since this has been such a controversial issue with stem cell technology?
A: Dr. James Musick, Chief Executive Officer
There are two major types of stem cells, embryonic stem cells and adult stem cells. Embryonic stem cells are present in embryos and their use may result in destruction of embryos and that process has created opposition to this work on ethical and religious grounds. However, adult stem cells are present in numerous adult tissues and their use does not involve sacrifice of embryos. Our work involves use of adult stem cells exclusively and our stem cell products are derived from human cord blood by methods that involve purification of the stem cells from other cells in blood such as red blood cells.
Also, Vitro and others are working to develop new methods for generation of embryonic stem cells from adult cells without using embryonic cells. These methods include reprogramming of adult cells to gain the ability to differentiate into any cell of the body, which is the hallmark of embryonic stem cells. Further development of this work may allow us to receive all benefits of embryonic stem cells by using adult cells and thus obviate many of the ethical objections to stem cell research.
It is also important to realize that there are tremendous potential benefits of stem cell therapy in treating many conditions that are presently untreatable or under treated. This field is rapidly advancing and there are regular reports of new clinical applications of stem cells that appear almost daily. Recently there was a report of successful treatment of enlarged heart with adult stem cells of the type that Vitro manufactures. Enlargement of the heart can be a serious consequence of heart attack.
Q Investorideas.com
Your business plan is to target niche markets in research and drug development that do not require FDA pre-market approval. Can you give us examples of those markets and the opportunity it represents for the company?
A: Dr. James Musick, Chief Executive Officer
A current niche market segment in the stem cell sector is cell culture media which is used for growth and differentiation of stem cells in a laboratory environment. Culture media is a complex solution that provides cells with nutrients needed to survive outside of the body. Vitro has developed media for culture of a certain type of stem cells called mesenchymal stem cells and our media possesses many competitive advantages including numerous performance advantages and ease of use characteristics. This market is estimated to be $1.2 billion per year in 2015 and with our superior products, and we are positioned to gain a substantial share of this market. While our present products don't require FDA approval for marketing, we are currently developing media for clinical applications that will require FDA approval as a medical device. This is a relatively straight forward process since the product is not a drug or biologic product. Our media may then be used to expand or differentiate adult stem cells prior to their transplantation for therapeutic use. This is an important aspect of our current business development that we anticipate will contribute substantially to our revenue and earnings growth in the near term.
Q: Investorideas.com
The company recently announced increased income of $200,000 through license fees obtained by licensing fertility drug patents, products and technology and that this allows the Company to monetize previously written-off assets through income from license fees and potential sales royalties while also pursuing additional product revenues through sales of its stem cell products.
Can you give us more detail and insight to this and how it benefits the company?
A: Dr. James Musick, Chief Executive Officer.
Vitro had previously patented methods for purification and generation of FSH from immortalized cells. FSH (follicle stimulating hormone) is a fertility hormone used in In-Vitro Fertilization (IVF) procedures to treat infertility. This represents a substantial and expanding global market since many couples have difficulty conceiving. Our patented FSH technology was part of our prior manufacturing of antigens for diagnostic uses that was the focus of the Company's operation during the 1990's. However, the patents were viewed as impaired for accounting purposes and were thus written off of the Company's balance sheet. This license agreement brought in license fees of $200,000 and also provides Vitro with royalty payments from sales of licensed products. The license fees will be reported as income and used to payoff a $200,000 debt that the Company had to the licensee. Our accounting and auditing team is now preparing our Form 10Q for this reporting period that will reflect all of the details of this transaction. We anticipate filing this report on or before its due date in mid-June. The royalty payments offer the Company an opportunity to realize additional income as the licensee sells products derived from this license.
Our present operations are focused on generation of revenue from our stem cell products that include: a) human mesenchymal stem cells and derivatives, b) cell culture media, and c) test kits for determination of stem cell quality, potency and response to toxic agents. Thus the license agreement for our fertility treatment technology allows revenue recognition from the Company's patented technology for production of FSH as well.
About Vitro Diagnostics, Inc. (OTCQB: VODG)
Vitro Diagnostics, Inc. dba Vitro Biopharma (OTCQB: VODG) (http://www.vitrobiopharma.com), owns U.S. patents for production of FSH, immortalization of pituitary cells, and a cell line that produces beta islets for use in treatment of diabetes. Vitro also owns a pending international patent for generation of pluripotent stem cells. Vitro's mission is "Harnessing the Power of Cells™" for the advancement of regenerative medicine to its full potential. Vitro operates within a modern biotechnology manufacturing, R&D and corporate facility in Golden, Colorado. Vitro manufactures and sells "Tools for Stem Cell and Drug Development™", including human mesenchymal stem cells and derivatives, optimized media for stem cell self-renewal and lineage-specific differentiation. Vitro recently formed a strategic alliance with HemoGenix®, Inc. (http://www.hemogenix.com/) to jointly manufacture and distribute Lumenesc™ and LumiSTEM™ quantitative assays for determination of stem cell quality, potency and response to toxic agents.
Recent News;
Stem Cell Stock Vitro (OTCQB: VODG) Announces Progress in the Achievement of Profitability
Revenue Increase Due to Licensing Fertility Drug Patents, Products and Technology
Full News: http://www.investorideas.com/CO/VODG/news/2011/05031.asp
More info:
Visit the VODG company profile on Investorideas.com
Visit the Biotech stocks directory at Investorideas.com
Request news and info on VODG
Sign up for the free investor news letter and get stock alerts in leading sectors!
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising .
Disclosure: VODG is a paid showcase stem cell stock on Investorideas.com (one month $1000)
www.InvestorIdeas.com/About/Disclaimer.asp
Safe Harbor Statement
This release contains certain "forward-looking statements" relating to the business of the Company and its subsidiary companies. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors.
www.Investorideas.com
Dawn Van Zant: 800-665-0411 - dvanzant@investorideas.com
Source - Investorideas.com
POINT ROBERTS, Wash., May 20,2011 - www.InvestorIdeas.com, a leader in investor research including biotech and stem cell stocks, issues a Q&A with Dr. James Musick, Chief Executive Officer of stem cell company, Vitro Diagnostics, Inc. dba Vitro Biopharma (OTCQB: VODG).
Q Investorideas.com
Your company's stem cell technology focuses on adult stem cells that are derived from human tissues without sacrifice of embryos. Can you give us more detail and explain how; since this has been such a controversial issue with stem cell technology?
A: Dr. James Musick, Chief Executive Officer
There are two major types of stem cells, embryonic stem cells and adult stem cells. Embryonic stem cells are present in embryos and their use may result in destruction of embryos and that process has created opposition to this work on ethical and religious grounds. However, adult stem cells are present in numerous adult tissues and their use does not involve sacrifice of embryos. Our work involves use of adult stem cells exclusively and our stem cell products are derived from human cord blood by methods that involve purification of the stem cells from other cells in blood such as red blood cells.
Also, Vitro and others are working to develop new methods for generation of embryonic stem cells from adult cells without using embryonic cells. These methods include reprogramming of adult cells to gain the ability to differentiate into any cell of the body, which is the hallmark of embryonic stem cells. Further development of this work may allow us to receive all benefits of embryonic stem cells by using adult cells and thus obviate many of the ethical objections to stem cell research.
It is also important to realize that there are tremendous potential benefits of stem cell therapy in treating many conditions that are presently untreatable or under treated. This field is rapidly advancing and there are regular reports of new clinical applications of stem cells that appear almost daily. Recently there was a report of successful treatment of enlarged heart with adult stem cells of the type that Vitro manufactures. Enlargement of the heart can be a serious consequence of heart attack.
Q Investorideas.com
Your business plan is to target niche markets in research and drug development that do not require FDA pre-market approval. Can you give us examples of those markets and the opportunity it represents for the company?
A: Dr. James Musick, Chief Executive Officer
A current niche market segment in the stem cell sector is cell culture media which is used for growth and differentiation of stem cells in a laboratory environment. Culture media is a complex solution that provides cells with nutrients needed to survive outside of the body. Vitro has developed media for culture of a certain type of stem cells called mesenchymal stem cells and our media possesses many competitive advantages including numerous performance advantages and ease of use characteristics. This market is estimated to be $1.2 billion per year in 2015 and with our superior products, and we are positioned to gain a substantial share of this market. While our present products don't require FDA approval for marketing, we are currently developing media for clinical applications that will require FDA approval as a medical device. This is a relatively straight forward process since the product is not a drug or biologic product. Our media may then be used to expand or differentiate adult stem cells prior to their transplantation for therapeutic use. This is an important aspect of our current business development that we anticipate will contribute substantially to our revenue and earnings growth in the near term.
Q: Investorideas.com
The company recently announced increased income of $200,000 through license fees obtained by licensing fertility drug patents, products and technology and that this allows the Company to monetize previously written-off assets through income from license fees and potential sales royalties while also pursuing additional product revenues through sales of its stem cell products.
Can you give us more detail and insight to this and how it benefits the company?
A: Dr. James Musick, Chief Executive Officer.
Vitro had previously patented methods for purification and generation of FSH from immortalized cells. FSH (follicle stimulating hormone) is a fertility hormone used in In-Vitro Fertilization (IVF) procedures to treat infertility. This represents a substantial and expanding global market since many couples have difficulty conceiving. Our patented FSH technology was part of our prior manufacturing of antigens for diagnostic uses that was the focus of the Company's operation during the 1990's. However, the patents were viewed as impaired for accounting purposes and were thus written off of the Company's balance sheet. This license agreement brought in license fees of $200,000 and also provides Vitro with royalty payments from sales of licensed products. The license fees will be reported as income and used to payoff a $200,000 debt that the Company had to the licensee. Our accounting and auditing team is now preparing our Form 10Q for this reporting period that will reflect all of the details of this transaction. We anticipate filing this report on or before its due date in mid-June. The royalty payments offer the Company an opportunity to realize additional income as the licensee sells products derived from this license.
Our present operations are focused on generation of revenue from our stem cell products that include: a) human mesenchymal stem cells and derivatives, b) cell culture media, and c) test kits for determination of stem cell quality, potency and response to toxic agents. Thus the license agreement for our fertility treatment technology allows revenue recognition from the Company's patented technology for production of FSH as well.
About Vitro Diagnostics, Inc. (OTCQB: VODG)
Vitro Diagnostics, Inc. dba Vitro Biopharma (OTCQB: VODG) (http://www.vitrobiopharma.com), owns U.S. patents for production of FSH, immortalization of pituitary cells, and a cell line that produces beta islets for use in treatment of diabetes. Vitro also owns a pending international patent for generation of pluripotent stem cells. Vitro's mission is "Harnessing the Power of Cells™" for the advancement of regenerative medicine to its full potential. Vitro operates within a modern biotechnology manufacturing, R&D and corporate facility in Golden, Colorado. Vitro manufactures and sells "Tools for Stem Cell and Drug Development™", including human mesenchymal stem cells and derivatives, optimized media for stem cell self-renewal and lineage-specific differentiation. Vitro recently formed a strategic alliance with HemoGenix®, Inc. (http://www.hemogenix.com/) to jointly manufacture and distribute Lumenesc™ and LumiSTEM™ quantitative assays for determination of stem cell quality, potency and response to toxic agents.
Recent News;
Stem Cell Stock Vitro (OTCQB: VODG) Announces Progress in the Achievement of Profitability
Revenue Increase Due to Licensing Fertility Drug Patents, Products and Technology
Full News: http://www.investorideas.com/CO/VODG/news/2011/05031.asp
More info:
Visit the VODG company profile on Investorideas.com
Visit the Biotech stocks directory at Investorideas.com
Request news and info on VODG
Sign up for the free investor news letter and get stock alerts in leading sectors!
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising .
Disclosure: VODG is a paid showcase stem cell stock on Investorideas.com (one month $1000)
www.InvestorIdeas.com/About/Disclaimer.asp
Safe Harbor Statement
This release contains certain "forward-looking statements" relating to the business of the Company and its subsidiary companies. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors.
www.Investorideas.com
Dawn Van Zant: 800-665-0411 - dvanzant@investorideas.com
Source - Investorideas.com
Vitro Diagnostics, Inc. dba Vitro Biopharma (OTCQB:VODG) is a profiled stem cell stock at Investorideas.com
Visit the VODG company profile on Investorideas.com
Visit the VODG company profile on Investorideas.com
Request News and Info on VODG
Disclosure, Disclaimer/ Disclosure -Vitro Diagnostics, Inc. dba Vitro Biopharma (OTCQB:VODG) showcase stem cell stock, one month, $one thousand, April - May 2011
Thursday, May 19, 2011
Leading Gold Stock Goldcorp (TSX: G, NYSE: GG) to Keynote ‘Follow the Money in Mining and Metals’ Online Investor Conference
line mining conference, Follow the Money in Mining and Metals, May 25th . Goldcorp is the fastest growing, lowest-cost senior gold producer with operations and development projects in politically stable jurisdictions throughout the Americas.
Other presenting Mining Stocks include Trueclaim Exploration Inc. (OTCQX: TRMNF) (TSX-V: TRM), Running Fox (TSX-V: RUN) (US OTC: RFXRF) (FRANKFURT: C8Q), Yale Resources Ltd. (TSX-V - YLL and Frankfurt - YAB), Currie Rose Resources Inc. (TSX.V: CUI) (OTC: CUIRF) and Strategic Resources (TSXV: UVR).
Industry speakers include Mr. Siddharth Rajeev, Of Fundamental Research Corp, Eric Coffin from Hard Rock Analyst, Peter Grandich, Lawrence Roulston and Stephen Whiteside of TheUpTrend.com.
The online conference is free to investors with login registration. The presentations will be an audio format with PowerPoint, averaging 10-15 minutes in length.
The event will be pre-recorded and go live May 25th starting at 9:00 a.m. EST. It will be archived for three months and available with login.
The conference pages will be featured for investors at both Investorideas.com and SmallCapvoice.com.
Learn More about the Mining Conference
http://www.investorideas.com/MSS/Conference.asp
Free Investor Sign-Up
http://www.smallcapvoice.com/ii_scv/investor-signup.html
Public Company Sign-Up
http://www.smallcapvoice.com/ii_scv/company-signup.html
Presenting Mining Stocks:
Goldcorp (TSX: G, NYSE: GG)
Goldcorp is the fastest growing, lowest-cost senior gold producer with operations and development projects in politically stable jurisdictions throughout the Americas. Our strong project pipeline is positioned to drive long-term, sustainable growth. A Canadian company headquartered in Vancouver, British Columbia, Goldcorp employs more than 11,500 people worldwide. Goldcorp is committed to responsible mining practices and is well-positioned to deliver sustained, industry leading growth and performance. We endeavor to deliver sustainable prosperity for our shareholders, employees, business partners and the communities in which we operate.
Contact
Jeff Wilhoit
VP, Investor Relations
(604) 696-3074
info@goldcorp.com
www.goldcorp.com
Trueclaim Exploration Inc. (OTCQX: TRMNF) (TSX-V: TRM)
Trueclaim Exploration Inc. is a mineral exploration company. Trueclaim is engaged in the acquisition and development of precious and base metals properties in strategically located areas, currently within Ontario and Arizona.The Company's current principal project is the former Scadding Gold Mine near Sudbury, Ontario. The Scadding claims are part of approximately 45,000 acres the Company has assembled in this area.
Contact
Jim Elbert
jelbert@trueclaim.ca
www.trueclaimexploration.com
Running Fox (TSX-V: RUN) (US OTC: RFXRF) (FRANKFURT: C8Q)
Running Fox is a Canadian growth-oriented resource company with mineral projects including US uranium and Canadian gold properties, oil and gas assets, and oilfield service operations.
Contact
Steven Schurman
Running Fox Resource Corp.
1 604 725 8868
www.foxgold.ca
Yale Resources Ltd. (TSX-V - YLL and Frankfurt - YAB)
Yale Resources Yale Resources Ltd. is an exploration and development company building value utilizing the Project Generator business model. With its Mexican operations based out of Hermosillo, Sonora, Yale is utilizing its extensive Mexican network to identify, acquire and advance projects of merit. Yale's partners are scheduled to spend greater than $1,000,000 on exploration on the Company's properties over the next 12 months.
Contact
Ian Foreman
info@yaleresources.com
www.yaleresources.com
Currie Rose Resources Inc. (TSX.V: CUI) (OTC: CUIRF)
Currie Rose Resources Inc. is a gold exploration company listed on the Toronto Venture Exchange under the symbol CUI-V, Frankfurt Exchange CDV, and U.S. OTC Market symbol CUIRF. The main focus is the Company's gold exploration projects in The Lake Victoria Gold Fields in Tanzania
IR contact
Harold Smith
harold@currierose.com
www.currierose.com
Strategic Resources (TSXV: UVR)
Strategic Resources is a Canadian based junior exploration company with uranium/vanadium exploration projects in Catron County, New Mexico, Rare Earth exploration projects in Lincoln County and Socorro County, New Mexico and a Lithium project in Malheur County, Oregon.
www.strategicresourcesinc.ca\
IR Contact
Malcolm Bucholtz
Supercyclereport@gmail.com
Media sponsors include the Streetwise Reports / Gold Report, mining investor sites Mine Snooper www.minesnooper.com , International Mining Research Inc (www.internationalminingresearch.com ) and the investor research magazine, the
Opportunist.
About www.InvestorIdeas.com: Investor Ideas that Can Change the World
Investor Ideas is a global financial media online destination specialized in sector investing content including mining and energy stocks.
About SmallCapVoice.com, Inc.: Specializing in Covering Small Cap Stocks & Providing Small Cap Investor Relations
Recognized corporate investor relations firm SmallCapVoice.com, Inc. is known for its ability to help emerging growth companies build a following among retail and institutional investors.
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
Disclosure: YLL is also a featured showcase stock on Investorideas.com
Learn more: http://www.investorideas.com/About/News/Clientspecifics.asp
For info on presenting as a public company, speaker or media sponsor contact
Cali Van Zant: 800-665-0411 - cvanzant@investorideas.com
Stuart T. Smith CEO
512-267-2430
ssmith@smallcapvoice.com
Source – Investorideas.com, SmallCapVoice.com
line mining conference, Follow the Money in Mining and Metals, May 25th . Goldcorp is the fastest growing, lowest-cost senior gold producer with operations and development projects in politically stable jurisdictions throughout the Americas.
Other presenting Mining Stocks include Trueclaim Exploration Inc. (OTCQX: TRMNF) (TSX-V: TRM), Running Fox (TSX-V: RUN) (US OTC: RFXRF) (FRANKFURT: C8Q), Yale Resources Ltd. (TSX-V - YLL and Frankfurt - YAB), Currie Rose Resources Inc. (TSX.V: CUI) (OTC: CUIRF) and Strategic Resources (TSXV: UVR).
Industry speakers include Mr. Siddharth Rajeev, Of Fundamental Research Corp, Eric Coffin from Hard Rock Analyst, Peter Grandich, Lawrence Roulston and Stephen Whiteside of TheUpTrend.com.
The online conference is free to investors with login registration. The presentations will be an audio format with PowerPoint, averaging 10-15 minutes in length.
The event will be pre-recorded and go live May 25th starting at 9:00 a.m. EST. It will be archived for three months and available with login.
The conference pages will be featured for investors at both Investorideas.com and SmallCapvoice.com.
Learn More about the Mining Conference
http://www.investorideas.com/MSS/Conference.asp
Free Investor Sign-Up
http://www.smallcapvoice.com/ii_scv/investor-signup.html
Public Company Sign-Up
http://www.smallcapvoice.com/ii_scv/company-signup.html
Presenting Mining Stocks:
Goldcorp (TSX: G, NYSE: GG)
Goldcorp is the fastest growing, lowest-cost senior gold producer with operations and development projects in politically stable jurisdictions throughout the Americas. Our strong project pipeline is positioned to drive long-term, sustainable growth. A Canadian company headquartered in Vancouver, British Columbia, Goldcorp employs more than 11,500 people worldwide. Goldcorp is committed to responsible mining practices and is well-positioned to deliver sustained, industry leading growth and performance. We endeavor to deliver sustainable prosperity for our shareholders, employees, business partners and the communities in which we operate.
Contact
Jeff Wilhoit
VP, Investor Relations
(604) 696-3074
info@goldcorp.com
www.goldcorp.com
Trueclaim Exploration Inc. (OTCQX: TRMNF) (TSX-V: TRM)
Trueclaim Exploration Inc. is a mineral exploration company. Trueclaim is engaged in the acquisition and development of precious and base metals properties in strategically located areas, currently within Ontario and Arizona.The Company's current principal project is the former Scadding Gold Mine near Sudbury, Ontario. The Scadding claims are part of approximately 45,000 acres the Company has assembled in this area.
Contact
Jim Elbert
jelbert@trueclaim.ca
www.trueclaimexploration.com
Running Fox (TSX-V: RUN) (US OTC: RFXRF) (FRANKFURT: C8Q)
Running Fox is a Canadian growth-oriented resource company with mineral projects including US uranium and Canadian gold properties, oil and gas assets, and oilfield service operations.
Contact
Steven Schurman
Running Fox Resource Corp.
1 604 725 8868
www.foxgold.ca
Yale Resources Ltd. (TSX-V - YLL and Frankfurt - YAB)
Yale Resources Yale Resources Ltd. is an exploration and development company building value utilizing the Project Generator business model. With its Mexican operations based out of Hermosillo, Sonora, Yale is utilizing its extensive Mexican network to identify, acquire and advance projects of merit. Yale's partners are scheduled to spend greater than $1,000,000 on exploration on the Company's properties over the next 12 months.
Contact
Ian Foreman
info@yaleresources.com
www.yaleresources.com
Currie Rose Resources Inc. (TSX.V: CUI) (OTC: CUIRF)
Currie Rose Resources Inc. is a gold exploration company listed on the Toronto Venture Exchange under the symbol CUI-V, Frankfurt Exchange CDV, and U.S. OTC Market symbol CUIRF. The main focus is the Company's gold exploration projects in The Lake Victoria Gold Fields in Tanzania
IR contact
Harold Smith
harold@currierose.com
www.currierose.com
Strategic Resources (TSXV: UVR)
Strategic Resources is a Canadian based junior exploration company with uranium/vanadium exploration projects in Catron County, New Mexico, Rare Earth exploration projects in Lincoln County and Socorro County, New Mexico and a Lithium project in Malheur County, Oregon.
www.strategicresourcesinc.ca\
IR Contact
Malcolm Bucholtz
Supercyclereport@gmail.com
Media sponsors include the Streetwise Reports / Gold Report, mining investor sites Mine Snooper www.minesnooper.com , International Mining Research Inc (www.internationalminingresearch.com ) and the investor research magazine, the
Opportunist.
About www.InvestorIdeas.com: Investor Ideas that Can Change the World
Investor Ideas is a global financial media online destination specialized in sector investing content including mining and energy stocks.
About SmallCapVoice.com, Inc.: Specializing in Covering Small Cap Stocks & Providing Small Cap Investor Relations
Recognized corporate investor relations firm SmallCapVoice.com, Inc. is known for its ability to help emerging growth companies build a following among retail and institutional investors.
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
Disclosure: YLL is also a featured showcase stock on Investorideas.com
Learn more: http://www.investorideas.com/About/News/Clientspecifics.asp
For info on presenting as a public company, speaker or media sponsor contact
Cali Van Zant: 800-665-0411 - cvanzant@investorideas.com
Stuart T. Smith CEO
512-267-2430
ssmith@smallcapvoice.com
Source – Investorideas.com, SmallCapVoice.com
Last call- Get your mining company in front of 50,000 investors online May 25th
Follow the Money in Mining and Metals May 25- Online mining investor conference
Its not too late to participate- we are recording up to May 23rd
We make it easy for you – record your presentation over the phone and send us a Powerpoint (optional)
The online event will feature leading industry experts speaking on the future of the mining sector, along with management of well- followed mining stocks.
The presentations will be an audio format with PowerPoint, averaging 10-15 minutes in length.
The event will be pre-recorded and go live May 25th starting at 9:00 a.m. EST.
Resource and investment speakers include Mr. Siddharth Rajeev, Of Fundamental Research Corp, Eric Coffin from Hard Rock Analyst, Peter Grandich, Lawrence Roulston and Stephen Whiteside of TheUpTrend.com.
Mining Stocks Presenting; Goldcorp (TSX: G, NYSE: GG), (TSX.V: CUI) (OTC: CUIRF), (TSXV: UVR), (TSX-V - YLL and Frankfurt - YAB) (TSX-V: RUN) (US OTC: RFXRF) (FRANKFURT: C8Q), (TSX-V: TRM)
What do you get?
We will send news on conference with your company info to over 50,000 investors
■10-20 minute presentation pre-recorded at your convenience on the phone
■Copy of the completed presentation to add to your site
■Be visible on Investorideas.com and SmallCapVoice.com
■Inclusion in press releases, marketing material up to the date of the conference
■Archived 90 days after
■All that for a one time fee of $1500
Added bonus- ask Investorideas.com for a free news release distribution through the Investorideas.com mining stocks newswire
Learn More about the Conference
http://www.smallcapvoice.com/ii_scv/index.html
Investor Sign-Up
http://www.smallcapvoice.com/ii_scv/investor-signup.html
Public Company Sign-Up -sign up and pay online
http://www.smallcapvoice.com/ii_scv/company-signup.html
About Investorideas.com
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
About SmallCapVoice.com, Inc.: Specializing in Covering Small Cap Stocks & Providing Small Cap Investor Relations
Recognized corporate investor relations firm SmallCapVoice.com, Inc. is known for its ability to help emerging growth companies build a following among retail and institutional investors.
For info on presenting as a public company, speaker or media sponsor contact
Cali Van Zant: 800-665-0411 - cvanzant@investorideas.com
Stuart T. Smith CEO
512-267-2430
ssmith@smallcapvoice.com
Sent to publicly traded mining stocks on the investor ideas mining stocks list . To be removed send back with remove or unsubscribe to shopkins@investorideas.com
Follow the Money in Mining and Metals May 25- Online mining investor conference
Its not too late to participate- we are recording up to May 23rd
We make it easy for you – record your presentation over the phone and send us a Powerpoint (optional)
The online event will feature leading industry experts speaking on the future of the mining sector, along with management of well- followed mining stocks.
The presentations will be an audio format with PowerPoint, averaging 10-15 minutes in length.
The event will be pre-recorded and go live May 25th starting at 9:00 a.m. EST.
Resource and investment speakers include Mr. Siddharth Rajeev, Of Fundamental Research Corp, Eric Coffin from Hard Rock Analyst, Peter Grandich, Lawrence Roulston and Stephen Whiteside of TheUpTrend.com.
Mining Stocks Presenting; Goldcorp (TSX: G, NYSE: GG), (TSX.V: CUI) (OTC: CUIRF), (TSXV: UVR), (TSX-V - YLL and Frankfurt - YAB) (TSX-V: RUN) (US OTC: RFXRF) (FRANKFURT: C8Q), (TSX-V: TRM)
What do you get?
We will send news on conference with your company info to over 50,000 investors
■10-20 minute presentation pre-recorded at your convenience on the phone
■Copy of the completed presentation to add to your site
■Be visible on Investorideas.com and SmallCapVoice.com
■Inclusion in press releases, marketing material up to the date of the conference
■Archived 90 days after
■All that for a one time fee of $1500
Added bonus- ask Investorideas.com for a free news release distribution through the Investorideas.com mining stocks newswire
Learn More about the Conference
http://www.smallcapvoice.com/ii_scv/index.html
Investor Sign-Up
http://www.smallcapvoice.com/ii_scv/investor-signup.html
Public Company Sign-Up -sign up and pay online
http://www.smallcapvoice.com/ii_scv/company-signup.html
About Investorideas.com
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
About SmallCapVoice.com, Inc.: Specializing in Covering Small Cap Stocks & Providing Small Cap Investor Relations
Recognized corporate investor relations firm SmallCapVoice.com, Inc. is known for its ability to help emerging growth companies build a following among retail and institutional investors.
For info on presenting as a public company, speaker or media sponsor contact
Cali Van Zant: 800-665-0411 - cvanzant@investorideas.com
Stuart T. Smith CEO
512-267-2430
ssmith@smallcapvoice.com
Sent to publicly traded mining stocks on the investor ideas mining stocks list . To be removed send back with remove or unsubscribe to shopkins@investorideas.com
Energy Stock Trading Alert; American Petro-Hunter (OTCBB: AAPH) Trading up over 15 % Following News on North Oklahoma Project
PointRoberts
, WA. - May 19, 2011 (Investorideas.com Energy Newswire) - www.InvestorIdeas.com, a leader in sector research including oil and gas stocks, releases a trading alert and stock chart for showcase energy company American Petro-Hunter Inc (OTCBB: AAPH). Thestock is trading at $0.52, up 0.07 (15.56%), following news yesterday announcing the spud of the NOM1H Horizontal well at the Company's North Oklahoma Project.
Recent News:
American Petro-Hunter (OTCBB: AAPH) Commences Spud of Horizontal Well at North Oklahoma Project
SCOTTSDALE , AZ - May 18, 2011 (Investorideas.com energy newswire) - American Petro-Hunter, Inc. (OTC.BB: AAPH) ("American Petro-Hunter" or the "Company") today is pleased to announce the spud of the NOM1H Horizontal well at the Company's North Oklahoma Project. Drilling commenced yesterday with the setting of surface casing and the well is drilling ahead.
Full News: http://www.investorideas.com/CO/AAPH/news/2011/05181.asp
About American Petro-Hunter, Inc. (OTC.BB: AAPH)
The Company is a goal-oriented exploration and production (E&P) Company aiming to become an intermediate level oil and gas producer within 12 months. The Company is in production at the Poston Project in Trego County, Kansas and the North Oklahoma Project. With the achievable target of becoming a 1000 BOE producer as our goal, American Petro-Hunter is actively on the "hunt" for domestic petroleum assets. Visit us at: www.americanpetrohunter.com
Research Report on American Petro-hunter Inc (OTCBB: AAPH)
www.aaphreport.com
American Petro-hunter Inc (OTCBB: AAPH) is a showcase Oil and Gas stock on Investorideas.com (please read disclosure and disclaimers)
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/AAPH/
Request info:
http://www.investorideas.com/Resources/Newsletter.asp
About Investor Ideas Oil and Gas portal: OilandGasStocksNews.com is a global meeting place for investors and industry following the energy sector, within Investorideas.com. Global visitors use the site daily
to research the latest news, articles, audio, research reports and our oil and gas and natural gas stock directories.
Research more oil and gas stocks with the oil and gas stock directory
http://www.investorideas.com/OGSN/Stock_List.asp
Disclaimer: The following American Petro-Hunter Inc news is paid for by third party on behalf of showcase energy stock AAPH (averages 2000 per month). Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stocklists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising .
The research report mentioned in this article is the content and opinion of Grass Roots Research and Distribution, Inc., not Investorideas.com or its related sites.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
C Van Zant: 800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
Point
Recent News: American Petro-Hunter (OTCBB: AAPH) Commences Spud of Horizontal Well at North Oklahoma Project
SCOTTSDALE , AZ - May 18, 2011 (Investorideas.com energy newswire) - American Petro-Hunter, Inc. (OTC.BB: AAPH) ("American Petro-Hunter" or the "Company") today is pleased to announce the spud of the NOM1H Horizontal well at the Company's North Oklahoma Project. Drilling commenced yesterday with the setting of surface casing and the well is drilling ahead.
Full News: http://www.investorideas.com/CO/AAPH/news/2011/05181.asp
About American Petro-Hunter, Inc. (OTC.BB: AAPH)
The Company is a goal-oriented exploration and production (E&P) Company aiming to become an intermediate level oil and gas producer within 12 months. The Company is in production at the Poston Project in Trego County, Kansas and the North Oklahoma Project. With the achievable target of becoming a 1000 BOE producer as our goal, American Petro-Hunter is actively on the "hunt" for domestic petroleum assets. Visit us at: www.americanpetrohunter.com
Research Report on American Petro-hunter Inc (OTCBB: AAPH)
www.aaphreport.com
American Petro-hunter Inc (OTCBB: AAPH) is a showcase Oil and Gas stock on Investorideas.com (please read disclosure and disclaimers)
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/AAPH/
Request info:
http://www.investorideas.com/Resources/Newsletter.asp
About Investor Ideas Oil and Gas portal: OilandGasStocksNews.com is a global meeting place for investors and industry following the energy sector, within Investorideas.com. Global visitors use the site daily
to research the latest news, articles, audio, research reports and our oil and gas and natural gas stock directories.
Research more oil and gas stocks with the oil and gas stock directory
http://www.investorideas.com/OGSN/Stock_List.asp
Disclaimer: The following American Petro-Hunter Inc news is paid for by third party on behalf of showcase energy stock AAPH (averages 2000 per month). Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock
The research report mentioned in this article is the content and opinion of Grass Roots Research and Distribution, Inc., not Investorideas.com or its related sites.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
C Van Zant: 800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
Visit the AAPH showcase profile at Investorideas.com
Request News and Info on AAPH
Disclosure, Disclaimer/ AAPH is a paid advertising client on Investorideas.com.
American Petro-hunter Inc. (AAPH.OB) Oct 2010 - one month showcase energy stock on Investorideas.com and energy portals and blogs (three thousand per month)
Request News and Info on AAPH
Disclosure, Disclaimer/ AAPH is a paid advertising client on Investorideas.com.
American Petro-hunter Inc. (AAPH.OB) Oct 2010 - one month showcase energy stock on Investorideas.com and energy portals and blogs (three thousand per month)
Biotech Stock Alert; Aethlon Medical (OTCBB: AEMD) Introduces the Aethlon ADAPT System
SAN DIEGO � May 19, 2011 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB: AEMD) announces the introduction of the Aethlon ADAPT™ system, an adaptive dialysis-like affinity platform technology that provides a novel and potentially expedited commercialization pathway for monoclonal antibodies and other affinity drug agents. The platform technology allows for single or multiple biologic agents to be immobilized within a therapeutic filtration design that results in a significantly less burdensome medical device regulatory approval pathway compared with the pathway for drugs or biologics.
The Company will market the Aethlon ADAPT™ system to drug developers as the basis for new therapeutic devices that target high-risk disease conditions. The Aethlon ADAPT™ system allows for the selective removal of disease-related particles from the entire circulatory system without the loss of essential blood components. It eliminates the need to infuse drug agents into the body as blood filtration occurs outside of the body. As a result, new devices evolved from this platform will not add drug toxicity or drug-drug interaction risks if combined with other therapies. The Aethlon ADAPT™ system also provides the potential to immobilize greater quantities of therapeutic drug agents compared with amounts that can be safely administered systemically. The platform may also be utilized to immobilize a cocktail of drug agents within a single device to address multiple factors underlying a single disease condition.
"The Aethlon ADAPT™ system provides the drug industry a new regulatory and commercialization pathway for their monoclonal antibodies and affinity drug agents," stated Aethlon CEO Jim Joyce. "The timing for introducing our platform could not be better considering the scope of increasing and unpredictable regulatory challenges faced by therapeutic drug developers."
The genesis of the Aethlon ADAPT™ system is the Aethlon Hemopurifier�, a broad-spectrum antiviral device that immobilizes a single lectin-affinity agent to bind circulating viruses, immunosuppressive proteins and disease-enhancing exosomes associated with both infectious diseases and cancer. Human studies of the Hemopurifier� have demonstrated average viral-load reductions exceeding 50% during four-hour treatment periods in individuals infected with hepatitis C virus (HCV) and HIV, without the administration of antiviral drugs. A human study is now underway to test the ability of the Aethlon Hemopurifier� to improve clinical outcomes in patients receiving HCV drug therapy.
On April 1, 2011 the Company leveraged the principles of the Aethlon ADAPT™ system to propose a new device that would reduce the incidence of sepsis in wounded military personnel through a contract response to a dialysis-like therapeutics program offered by the Defense Advanced Research Projects Agency (DARPA). Aethlon is currently preparing a submission to another government agency that would propose the use of the Aethlon ADAPT™ system to create a third company-owned therapeutic device.
Since the beginning of 2011, Aethlon Medical has expanded its channels for early revenue generation beyond the candidate use of its Hemopurifier� in HCV care. In addition to potential development revenues from new devices created from the Aethlon ADAPT™ system, the Company has positioned itself to be a candidate recipient of contract and grant income from government agency solicitations, and is considering the launch of a research diagnostic tool line developed by its wholly owned subsidiary Exosome Sciences, Inc.
About Aethlon Medical
At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.
Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.
Human studies have documented the ability of our Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs. However, our initial clinical and commercialization focus is to establish our Hemopurifier® as an adjunct therapy to enhance the benefit of both infectious disease and cancer treatment regimens. In this regard, we plan to commercialize our Hemopurifier® in India as we advance our clinical strategies in the United States and the European Union. In vitro studies conducted by government and non-government research institutes have also verified that our Hemopurifier® has broad-spectrum capabilities against bioterror and emerging pandemic threats. These studies have confirmed the capture of Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.
As a therapeutic device, the Hemopurifier® provides us with a pipeline into four significant market opportunities:
In design, our Hemopurifier® is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system. In application, blood circulation is established into the Hemopurifier® via a catheter or other blood access device. Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier® in as little as 15 minutes.
Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) is focused on the development of exosome-targeted products and services that improve cancer diagnosis, provide post-treatment cancer surveillance, and aid in the discovery of biomarkers that allow doctors to optimize patient therapy. Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the company's ability to commercialize its Hemopurifier® in India, capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
John P. Salvador
Director, Communications & Investor Relations
858.459.7800 x307
jps@aethlonmedical.com
SAN DIEGO � May 19, 2011 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB: AEMD) announces the introduction of the Aethlon ADAPT™ system, an adaptive dialysis-like affinity platform technology that provides a novel and potentially expedited commercialization pathway for monoclonal antibodies and other affinity drug agents. The platform technology allows for single or multiple biologic agents to be immobilized within a therapeutic filtration design that results in a significantly less burdensome medical device regulatory approval pathway compared with the pathway for drugs or biologics.
The Company will market the Aethlon ADAPT™ system to drug developers as the basis for new therapeutic devices that target high-risk disease conditions. The Aethlon ADAPT™ system allows for the selective removal of disease-related particles from the entire circulatory system without the loss of essential blood components. It eliminates the need to infuse drug agents into the body as blood filtration occurs outside of the body. As a result, new devices evolved from this platform will not add drug toxicity or drug-drug interaction risks if combined with other therapies. The Aethlon ADAPT™ system also provides the potential to immobilize greater quantities of therapeutic drug agents compared with amounts that can be safely administered systemically. The platform may also be utilized to immobilize a cocktail of drug agents within a single device to address multiple factors underlying a single disease condition.
"The Aethlon ADAPT™ system provides the drug industry a new regulatory and commercialization pathway for their monoclonal antibodies and affinity drug agents," stated Aethlon CEO Jim Joyce. "The timing for introducing our platform could not be better considering the scope of increasing and unpredictable regulatory challenges faced by therapeutic drug developers."
The genesis of the Aethlon ADAPT™ system is the Aethlon Hemopurifier�, a broad-spectrum antiviral device that immobilizes a single lectin-affinity agent to bind circulating viruses, immunosuppressive proteins and disease-enhancing exosomes associated with both infectious diseases and cancer. Human studies of the Hemopurifier� have demonstrated average viral-load reductions exceeding 50% during four-hour treatment periods in individuals infected with hepatitis C virus (HCV) and HIV, without the administration of antiviral drugs. A human study is now underway to test the ability of the Aethlon Hemopurifier� to improve clinical outcomes in patients receiving HCV drug therapy.
On April 1, 2011 the Company leveraged the principles of the Aethlon ADAPT™ system to propose a new device that would reduce the incidence of sepsis in wounded military personnel through a contract response to a dialysis-like therapeutics program offered by the Defense Advanced Research Projects Agency (DARPA). Aethlon is currently preparing a submission to another government agency that would propose the use of the Aethlon ADAPT™ system to create a third company-owned therapeutic device.
Since the beginning of 2011, Aethlon Medical has expanded its channels for early revenue generation beyond the candidate use of its Hemopurifier� in HCV care. In addition to potential development revenues from new devices created from the Aethlon ADAPT™ system, the Company has positioned itself to be a candidate recipient of contract and grant income from government agency solicitations, and is considering the launch of a research diagnostic tool line developed by its wholly owned subsidiary Exosome Sciences, Inc.
About Aethlon Medical
At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.
Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.
Human studies have documented the ability of our Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs. However, our initial clinical and commercialization focus is to establish our Hemopurifier® as an adjunct therapy to enhance the benefit of both infectious disease and cancer treatment regimens. In this regard, we plan to commercialize our Hemopurifier® in India as we advance our clinical strategies in the United States and the European Union. In vitro studies conducted by government and non-government research institutes have also verified that our Hemopurifier® has broad-spectrum capabilities against bioterror and emerging pandemic threats. These studies have confirmed the capture of Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.
As a therapeutic device, the Hemopurifier® provides us with a pipeline into four significant market opportunities:
- Cancer: A treatment candidate to improve patient responsiveness to established cancer therapies by removing immunosuppressive exosomes from circulation.
- Hepatitis-C Virus (HCV): As an adjunct therapy to accelerate viral load reduction at the outset of standard of care drug regimens.
- Human Immunodeficiency Virus (HIV): Provides a potential therapeutic option for HIV-infected individuals to manage disease progression once they become resistant to antiviral drug regimens.
- Bioterror and Pandemic Threats: Represents the most advanced broad-spectrum strategy to address untreatable bioterror and emerging pandemic threats.
In design, our Hemopurifier® is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system. In application, blood circulation is established into the Hemopurifier® via a catheter or other blood access device. Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier® in as little as 15 minutes.
Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) is focused on the development of exosome-targeted products and services that improve cancer diagnosis, provide post-treatment cancer surveillance, and aid in the discovery of biomarkers that allow doctors to optimize patient therapy. Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the company's ability to commercialize its Hemopurifier® in India, capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
John P. Salvador
Director, Communications & Investor Relations
858.459.7800 x307
jps@aethlonmedical.com
AETHLON MEDICAL INC (OTC BB: AEMD) is a Showcase biotech, biodefense and defense stock on Investorideas.com ($one thousand five hundred per month, $five thousand per month in 144 stock)
Effective March 15, 2011
Effective March 15, 2011
Subscribe to:
Posts (Atom)